Haemonetics CFO Departs; Interim Appointed
Ticker: HAE · Form: 8-K · Filed: Mar 3, 2025 · CIK: 313143
| Field | Detail |
|---|---|
| Company | Haemonetics Corp (HAE) |
| Form Type | 8-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-departure, cfo-change, interim-appointment
TL;DR
Haemonetics CFO Brenda Foster out, Brian Smith steps in as interim. Big changes brewing?
AI Summary
Haemonetics Corporation announced on March 3, 2025, the departure of its Chief Financial Officer, Brenda L. Foster, effective March 1, 2025. The company also announced the appointment of Brian J. Smith as interim CFO. Additionally, the filing disclosed compensatory arrangements for certain officers and included financial statements and exhibits.
Why It Matters
A change in CFO can signal shifts in financial strategy or performance, impacting investor confidence and the company's stock price.
Risk Assessment
Risk Level: medium — A CFO departure, especially without a permanent replacement named, can introduce uncertainty regarding financial leadership and future strategy.
Key Players & Entities
- Haemonetics Corporation (company) — Registrant
- Brenda L. Foster (person) — Departing Chief Financial Officer
- March 3, 2025 (date) — Date of Report
- March 1, 2025 (date) — Effective date of CFO departure
- Brian J. Smith (person) — Interim Chief Financial Officer
FAQ
Who is Brenda L. Foster and what was her role at Haemonetics Corporation?
Brenda L. Foster was the Chief Financial Officer of Haemonetics Corporation and her departure was effective March 1, 2025.
Who has been appointed as the interim Chief Financial Officer?
Brian J. Smith has been appointed as the interim Chief Financial Officer.
What is the effective date of Brenda L. Foster's departure?
Brenda L. Foster's departure was effective March 1, 2025.
What other items are included in this 8-K filing besides the officer changes?
The filing also discloses compensatory arrangements for certain officers and includes financial statements and exhibits.
What is the principal executive office address for Haemonetics Corporation?
The principal executive offices are located at 125 Summer Street, Boston, MA 02110.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 3, 2025 by Brenda L. Foster regarding HAEMONETICS CORP (HAE).